Quantcast

Latest Prostate cancer Stories

2014-08-12 08:30:36

SYDNEY, Aug. 12, 2014 /PRNewswire/ -- The Australian biotechnology company, Novogen Limited (ASX: NRT; NASDAQ: NVGN), today announced receipt of funding from the FSHD Global Research Foundation as part of the Company's efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD). http://photos.prnewswire.com/prnvar/20131220/NY36990LOGO FSHD is one of the most common forms of muscular dystrophy and genetic hereditary...

2014-08-12 08:29:43

DUBLIN, Aug. 12, 2014 /PRNewswire/ -- Research and Markets(http://www.researchandmarkets.com/research/cmxtrz/brachytherapy) has announced the addition of the "Brachytherapy - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Brachytherapy in US$ Thousands. The report provides separate comprehensive analytics for the US, Canada, Japan Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided...

2014-08-11 08:29:51

DALLAS, August 11, 2014 /PRNewswire/ -- The global digital pathology market is expected to grow at 11.8% CAGR to reach an estimated $437 million by 2018. In 2013, the North American market was valued at $128.9 million and accounted for the largest share of the global digital pathology market...

2014-08-11 08:29:18

Trial Progressing On Track; BETHESDA, Md., Aug. 11, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced an update about the Company's Phase III clinical trial of DCVax®-L for Glioblastoma multiforme (GBM) brain cancer in conjunction with the Company's separate announcement today about certain changes to the Phase III trial. The update from the Company...

2014-08-08 12:25:25

ROCKVILLE, Md., Aug. 8, 2014 /PRNewswire/ -- OncoPlex Diagnostics has developed a quantitative androgen receptor (AR) assay to add to their Breast Cancer Proteomic Panel. The OncoPlex Diagnostics Breast Panel simultaneously measures multiple clinically-relevant tumor proteins using mass spectrometry to better inform the oncologist on therapy selection. The Breast Cancer Proteomic Panel with the inclusion of AR was featured in a presentation at the 13(th) Annual International Future...

2014-08-07 16:28:34

17% Increase in Test Volume, 11% Increase in Total Revenue and 29% Increase in International Product Revenue Compared to Prior Year REDWOOD CITY, Calif., Aug. 7, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2014. Product revenue was $70.5 million in the second quarter of 2014, compared with $63.7 million for the second quarter of 2013, an increase of 11 percent. There was no contract revenue in...

2014-08-07 16:28:19

Conference call to be held on Thursday, August 7, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 7, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced second quarter 2014 financial results. Clinical Developments and Anticipated Milestones -- Apatorsen -- The OncoGenex apatorsen development program includes seven Phase 2 trials in four tumor types,...

2014-08-06 16:28:56

--Brand Expands New Apparel and Accessories to Successful Pediatric, Breast, and Prostate Cancer Awareness Collections, Aiding in the Fight Against Cancer-- IRVINE, Calif., Aug. 6, 2014 /PRNewswire/ -- ASICS America is proud to announce its third year of cancer awareness product collections with the ASICS Accelerate Hope(TM) initiative. Based on the results of two consecutive years of successful cancer cause campaigns, ASICS has amplified the Accelerate Hope(TM) program to include...

2014-08-06 12:29:18

The Majority of Surveyed Non-Prescribers Anticipate Prescribing Xofigo Within the Next Six Months, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 6, 2014 /PRNewswire/ -- Decision Resources Group finds that at one year post-launch in the United States, over two thirds of surveyed U.S. medical oncologists have prescribed Bayer HealthCare's alpha-emitting radiopharmaceutical Xofigo. The majority of current non-prescribers indicated that they expect to prescribe...

2014-08-06 12:28:13

Study Correlates Immune Response with Improved Survival in Prostate Cancer Patients after Receiving the Antigen Express Novel Immunotherapeutic AE37 WORCESTER, Mass. and TORONTO, Aug. 6, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of a follow-up study from a Phase I clinical trial of the immunotherapeutic agent AE37 in patients with prostate cancer. The study demonstrates an association between a specific immune...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'